• Limor Gishri was promoted to CEO of Allium Medical Group (Caesarea, Israel). Gishri previously was CFO and VP of business development, sales & marketing. Prior to joining Allium, Gishri was at the law firm of Shiboleth, Yisraeli, Roberts, Zisman & Co., in the hi-tech department. Allium makes site-specific stents for various uses with applications in the urinary and gastro-intestinal tract.

• AMDL (Tustin, California) reported the promotion of its CFO, Akio Ariura, to COO and CFO. The company is also expanding its management team with the addition of Christopher Gee as director of international marketing and sales and Raymond Gatchalian as director of compliance and information technology. Ariura joined AMDL in 2006 as CFO. Gee is a former Apple executive and tech/biotech industry veteran with extensive IT, business operations, and international sales and marketing management experience. Gatchalian has an extensive background in IT audit and compliance. AMDL is a biopharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement and cosmetic products.

• Home Diagnostics (Fort Lauderdale, Florida) said that the board has retained the executive search firm DavenportMajor to recruit a successor to President/CEO J. Richard Damron Jr., who will be departing the company following a transition. Damron will remain in his present role until a transition is completed, which is expected to be in the first half of 2009. Home Diagnostics makes diabetes management solutions.

• InSite Vision (Alameda, California) said that Louis Drapeau, the company's VP/CFO since October 2007, has been named interim CEO. S. Kumar Chandrasekaran, PhD, will step down as CEO. Drapeau will lead the day-to-day operations of the company while retaining his current CFO responsibilities. In addition, Evan Melrose, MD, managing director of PTV Sciences since January 2003, has been named chairman of the company. InSite Vision makes ocular pharmaceutical products using its DuraSite bioadhesive polymer core technology to enable topical delivery and sustained release of existing drug molecules for reduced frequency of treatment and improved efficacy.

• Bobby Griffin has been elected to the board of directors of Salient Surgical Technologies (Dover, New Hampshire). Griffin is involved in venture capital activities at B.G. Holdings and is on the board of various discovery companies researching new applications or therapies in medicine and dentistry. Salient Surgical Technologies makes advanced energy devices for use in surgical procedures.

• Michael Kaminski, president/COO and a member of the board of Stereotaxis (St. Louis), will become CEO, effective Jan. 1. At that time, he will replace Bevil Hogg, who has served as CEO since 1997 and will remain a member of the company's board. Kaminski joined Stereotaxis in April 2002 as COO. Stereotaxis makes an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias.

• Gil Glover has been promoted to president/COO of TrailBlazer Health Enterprises (Dallas). Glover, a VP at TrailBlazer since 1999, takes over leadership of the company from Martha Mahaffey, who has retired after serving as president since 2005. TrailBlazer Health Enterprises is a diversified government contractor, providing services to Medicare and other government programs.

• Mete Sahin was named CFO of XLHealth (Baltimore). The company also has named two additional executives — Kevin Vetter as VP of operations and technology and Anita McCreavy as director of clinical quality. Sahin previously served as CFO for multiple UnitedHealth Group companies. Vetter has more than eight years of experience as a CIO for commercial and Medicare health plans. McCreavy previously worked for the company as a consultant. XLHealth is the owner and operator of Care Improvement Plus, one of the nation's largest chronic condition special needs plans.